Skip to content
Research Article Open access CC BY 4.0

Therapeutic Potential of the Dual Peroxisome Proliferator Activated Receptor (PPAR)/ Agonist Aleglitazar in Attenuating TNF-mediated Inflammation and Insulin Resistance in Human Adipocytes: A Review

Naser A. ElSawy

Asian Journal of Immunology · pp. 34–44 · Published 10 Dec 2019

Abstract

Aleglitazar, is a novel promising drug, that related to peroxisome proliferator-activated receptor (PPARα&γ) agonists which shows an ant-diabetic and anti-inflammatory characteristics. The goal of this study is to evaluate anti-inflammatory and anti-arthritic properties of Aleglitazar in arthritis models induced in experimental animals and to conclude the comparative ulcerogenic potential of diclofenac in type 2 diabetes animals. The anti-inflammatory characteristics of Aleglitazar will be investigated in Carrageenan-induced hind paw edema as acute inflammation. The Aim of the review: This study aims to assess anti-inflammatory and anti-arthritic activities of aleglitazar in arthritis models induced in experimental animals. It is to determine comparative ulcerogenic potential diclofenac in type 2 diabetic animals on gastric mucosa in rats.

PPAR Aleglitazar TNF inflammation insulin resistance adipocytes.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.